Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-2-17
pubmed:abstractText
Currently, no agent has been confirmed as preventing the fibrosing progression of non-alcoholic steatohepatitis (NASH). In this study, rosiglitazone was used in the clinical treatment of insulin resistance in patients with type 2 diabetes mellitus. However, its protective effect on non-alcoholic fibrosing steatohepatitis is not clear. The study aimed to elucidate the effect and the mechanism of rosiglitazone in inhibiting nutrition-related fibrosis in mice.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1502-7708
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
358-65
pubmed:meshHeading
pubmed-meshheading:18991162-Alanine Transaminase, pubmed-meshheading:18991162-Animals, pubmed-meshheading:18991162-Aspartate Aminotransferases, pubmed-meshheading:18991162-Blotting, Western, pubmed-meshheading:18991162-Connective Tissue Growth Factor, pubmed-meshheading:18991162-Fatty Liver, pubmed-meshheading:18991162-Hepatic Stellate Cells, pubmed-meshheading:18991162-Hypoglycemic Agents, pubmed-meshheading:18991162-Immunoenzyme Techniques, pubmed-meshheading:18991162-Liver Cirrhosis, pubmed-meshheading:18991162-Liver Function Tests, pubmed-meshheading:18991162-Male, pubmed-meshheading:18991162-Mice, pubmed-meshheading:18991162-Mice, Inbred C57BL, pubmed-meshheading:18991162-PPAR gamma, pubmed-meshheading:18991162-Thiazolidinediones, pubmed-meshheading:18991162-Transforming Growth Factor beta1
pubmed:year
2009
pubmed:articleTitle
Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
pubmed:affiliation
Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China. nanyuemin@163.com
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't